P138 Time trends for incidence and survival of epithelial ovarian, fallopian tube, peritoneal and undesignated site cancer in sweden 1960–2014 – a population-based survey of cancer registry data. (1st November 2019)

• Record Type: Journal Article
• Authors: Leandersson, P; Högberg, T; Dickman, P; Malander, S; Borgfeldt, C
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A142
• Page End: A142
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.200
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Analysis of survival trends in epithelial ovarian cancer with regard to age, tumour site and morphological subgroup in Sweden 1960 to 2014. Methodology: Nation-wide population-based study on data from the Swedish Cancer Registry. 46 350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal or undesignated site cancer 1960 to 2014 were included. Analyses of age-standardised incidence and relative survival (RS) were done and time trend graphs modelled according to age, tumour site and morphological subgroup. Results: Overall incidence of ovarian, tubal, peritoneal and undesignated site cancer declined since 1980. Median age at diagnosis increased. Serous cancer increased in incidence. RS at 1-, 2- and 5-years improved since 1960 although not for the youngest and the oldest patients. 10-year RS did not improve. Best RS was found for fallopian tube cancer and worst RS for undesignated site cancer. Among the histological subgroups endometrioid cancer had the best RS. RS improved most for endometrioid and mucinous cancer. Conclusion: Survival in epithelial ovarian, tubal, peritoneal and undesignated site cancer in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5 years from diagnosis but not long-term survival. Disclosure: Nothing to disclose.